A Transmission Model of the 2010 Cholera Epidemic in Haiti by A. Rinaldo et al.
References
1. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al; AIDS
Clinical Trials Group Study A5202 Team. Atazanavir plus ritonavir or efavirenz as part
of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154:445-
56. [PMID: 21320923]
2. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL,
et al; AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for
initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095-106. [PMID:
18480202]
3. Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of
noninferiority trials. Ann Intern Med. 2006;145:62-9. [PMID: 16818930]
4. Parienti JJ, Verdon R, Massari V. Methodological standards in non-inferiority AIDS
trials: moving from adherence to compliance. BMC Med Res Methodol. 2006;6:46.
[PMID: 16987409]
IN RESPONSE: Dr. Flandre raises important points regarding the
ACTG Study A5202 results; however, the abstract’s conclusion does
not stand alone. The Results section of the abstract and the Results
and Discussion sections of the manuscript state that the equivalence
boundary was not met. We do believe that the similarity in response
rates is relevant to clinicians considering these treatment options.
Differences in baseline HIV-1 RNA values have been addressed in a
secondary analysis adjusting for this as continuous and categorical
variables (!50 000 copies/mL, 50 000 to !100 000 copies/mL,
100 000 to !500 000 copies/mL, or !500 000 copies/mL), with
the treatment effect estimate showing similar results to the primary
analysis. The HRs and 95% CIs when baseline HIV-1 RNA was
analyzed as continuous and categorical variables were 1.11 (0.81 to
1.54) and 1.06 (0.77 to 1.47) for abacavir–lamivudine and 1.01
(0.70 to 1.46) and 1.04 (0.72 to 1.51) for tenofovir disoproxil
fumarate–emtricitabine, respectively.
Prespecified equivalence boundaries were based on the relative
treatment difference of the HR (specified as 0.71 to 1.40). The
paper’s Statistical Analysis section states that an HR of 1.40 with a
32% event rate would represent a 96-week difference in probability
of VF of approximately 10%. The VF rate makes the current equiv-
alence definition very strict. With the observed rate of approximately
15%, an HR of 1.40 would correspond to an approximately 5%
absolute difference, and a 10% difference would correspond to HR
boundaries of 0.56 to 1.77.
Dr. Kuchenbecker and colleagues are correct that the drugs
compared in this study were open-label; however, blinding protease
and nonnucleoside reverse transcriptase inhibitors is challenging and
rarely done in recent HIV treatment trials—we acknowledged this in
the manuscript as a limitation of the study. We stand by our state-
ment that A5202 was different in design and results from A5142 (1).
Unlike the A5142 study, the A5202 study randomly assigned pa-
tients to commonly used NRTIs in a blinded fashion and also used
atazanavir–ritonavir, which is a preferred agent; this is no longer true
for the lopinavir–ritonavir used in A5142 (2). Although the A5202
study was unable to declare equivalence, response rates by all other
measures were similar between the 2 regimens. Compared with efa-
virenz in the A5142 study, the time to VF was significantly shorter
with lopinavir–ritonavir (HR, 0.63 [CI 0.45 to 0.87]; P " 0.0006).
We agree with the commentators and acknowledged the rela-
tively high loss to follow-up in the manuscript. We did several sen-
sitivity analyses to address potential attrition bias (Appendix Table 2
in the article), including as-treated analyses in which time to VF
failure was censored at modification of the third drug that showed
results similar to those of the primary intention-to-treat analysis.
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A Transmission Model of the 2010 Cholera Epidemic in Haiti
TO THE EDITOR: The article by Tuite and colleagues (1) proposed a
spatially explicit scheme reproducing the sequence and the timing of
regional cholera epidemics through waterborne and person-to-person
transmission of cholera. Two additional modeling studies of the on-
going Haiti cholera outbreak and its controls were independently
and almost simultaneously published (2, 3). In particular, a similar
transmission model, based on a finer spatial detail of the affected
communities and on alternative descriptions of hydrologic and hu-
man mobility drivers of pathogen dispersal (4, 5), has been likewise
applied to the unfolding Haiti epidemic (3). Despite differences in
the assumptions, the results regarding the effect of control strategies,
such as vaccination and sanitation, are similar. However, the article
by Bertuzzo and colleagues (3) pointed out that larger intervention
efforts involve nontrivial effects, with sanitation exhibiting a
threshold-like behavior in effectiveness.
From a modeling standpoint, the main difference between the
approaches is that Tuite and colleagues (1) neglect the role of asymp-
tomatic patients who do not report to a hospital, which is suggested
to be a critical factor in cholera epidemics, particularly those in Haiti
(2, 3). Asymptomatic patients acquire immunity, thus reducing the
number of persons in a region who are susceptible to the disease.
Figure 4 in Tuite and colleagues’ article shows that their model with
realistic values of the basic reproductive number (R0 " 2.78 or 2.90)
fits the initial phases of the epidemic but would predict an excessive
number of reported cases at later stages. To overcome this, they
propose that the effective reproductive number decreases from 3 to
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0.5 in the first 3 months of the epidemic, owing to disease-control
interventions that would have effectively prevented thousands of
cases. A 6-fold decrease of the reproductive number—if asymptom-
atic patients are not accounted for and the compartment of suscep-
tibles is not depleted—implies a 6-fold decrease of transmission rates.
These figures seem unrealistic, especially compared with the
sanitation intervention that Tuite and colleagues analyzed (1): Pro-
viding vaccines or clean water to 500 000 persons clearly represents a
major effort largely exceeding the disease-control interventions ad-
opted in the first 3 months of cholera insurgence in Haiti, yet it
would lead to a much smaller decrease in the transmission rate. This
apparent paradox is solved by adopting a model in which asymptom-
atic infections are accounted for (2, 3). This does not require repro-
ductive numbers to decrease with time because of unspecified
disease-control measures to prevent an excess of persons who were
calculated to be infected, which is an artifact of neglecting asymp-
tomatic patients (2, 3).
Despite differences in methods, a comparative study on the
limits and validity of modeling large-scale epidemic management
suggests that such tools should be seen as essential components of
future control of cholera epidemics.
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IN RESPONSE: We welcome the opportunity to clarify our analysis
for Dr. Rinaldo and colleagues. We modeled a pool of infective
patients that included both hospitalized and nonhospitalized individ-
uals, but calibrated the model to reproduce hospitalized cases that
were accurately measured. Our analysis of vaccines and water was not
intended to represent the massive and far more robust multiagency
public health response to the Haitian cholera epidemic; rather, it was
intended to explore the projected relative effects of low levels of
vaccination and water distribution. We did not distinguish symp-
tomatic and asymptomatic cases in our model.
Dr. Rinaldo and colleagues suggest that the marked decline in the
rate of growth of Haiti’s cholera epidemic resulted from asymptomatic
infection of large numbers of individuals in the population, and that the
epidemic effectively stopped by itself. They suggest that our empirical
reduction in effective reproductive number (which they misstate as re-
duction in R0) is problematic and fails to capture the degree to which
population immunity resulted in transient control of the epidemic. Re-
cent events in Haiti show this thesis to be implausible, and our modeling
approach has unfortunately been somewhat validated by the recent large
surge in cholera cases in Haiti since early May 2011. This surge has been
particularly marked in the capital region and in the south of the country,
as our model projected (1).
It is important to distinguish the basic reproductive number of
a disease (R0), which is the average number of secondary cases of
infection created by a primary case introduced into a totally suscep-
tible population in the absence of intervention (2), from the effective
reproductive number, which is the reproductive number in the pres-
ence of immunity or intervention (often denoted Re). Dr. Rinaldo
and colleagues confuse these concepts. For Re to decline from around
3 to around 0.5 solely on the basis of immunity, approximately 85%
of the Haitian population would have had to be infected in a
3-month period (2). This would require implausibly short “serial
intervals” between cases for a disease with an R0 of 3 (3) and would
also have resulted in sufficient herd immunity to make the recent
epidemic surge in cholera cases impossible (2). Better data are needed
for the modeling and control of cholera in Haiti, but to be credible,
modelers need to consider the important and hard-to-measure effects
of public health responders in the successful control of epidemics.
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